Fujiwara Y, et al. - Dabrafenib was assessed in the context of safety and tolerability, pharmacokinetics and preliminary efficacy in Japanese patients. Based on the data obtained, the recommended regimen was well tolerated and rapidly absorbed administered as single- or multiple dose, and exhibited promising clinical activity in Japanese patients with BRAF mutated malignant melanoma. Findings revealed comparable safety and pharmacokinetic profiles compared with non-Japanese patients.